Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01391793
Other study ID # R01DK087870
Secondary ID R01DK087870
Status Completed
Phase Phase 3
First received
Last updated
Start date September 2011
Est. completion date March 30, 2018

Study information

Verified date June 2019
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study the investigators will determine whether corticosteroids given at the time of urinary tract infection help prevent permanent damage to the kidneys.


Description:

Because host inflammatory response is the final and most important step in the formation of renal scars, the use of anti-inflammatory agents may be the best strategy to reduce renal scarring. In animal studies, the use of corticosteroids has been shown to be effective in preventing post-pyelonephritic scarring. We will conduct a randomized, double-blind, placebo-controlled trial to determine the efficacy of 3 days of daily adjuvant dexamethasone on the incidence of renal scarring 4 to 6 months after a first febrile urinary tract infection (UTI). We hypothesize that the proportion of children with UTI who develop renal scarring will be lower among children who are treated with both dexamethasone and antibiotics as compared with children treated with antibiotics alone.


Recruitment information / eligibility

Status Completed
Enrollment 546
Est. completion date March 30, 2018
Est. primary completion date March 30, 2018
Accepts healthy volunteers No
Gender All
Age group 2 Months to 6 Years
Eligibility Inclusion Criteria:

- Age: 2 months to 6 years

- Pyuria: =10 white blood cells per cubic millimeter (WBC/mm3) in an uncentrifuged specimen or =5 white blood cells per high power field (WBC/hpf) in a centrifuged specimen or =1+ leukocyte esterase (LE) on dipstick

- Fever: documented temperature of at least 101 °F or 38.3°C, measured anywhere on the body either at home or at doctor's office within 24 hours of diagnosis

Exclusion Criteria:

- Other concurrent systemic bacterial infection(s) such as meningitis or pneumonia;

- Planned admission to intensive care unit;

- Known bacteremia;

- Previous protocol defined UTI;

- Known major urinary tract anomalies (severe hydronephrosis, ureterocele, urethral valve, solitary or profoundly small kidney, multicystic dysplastic kidney, neurogenic bladder, pelvic or fused kidney);

- Congenital/acquired immunodeficiency;

- Bag urine collection

- Chronic diseases that could potentially interfere with response to therapy, such as chronic gastrointestinal conditions (i.e. malabsorption, inflammatory bowel disease), liver/kidney failure;

- Allergy to dexamethasone

- Antibiotic use within 7 days of enrollment (except if given in the last 48 hours)

- Systemic use of corticosteroids or other immunomodulating agents within 14 days of enrollment

- History of Kawasaki disease

- Sickle cell disease (not trait)

Study Design


Intervention

Drug:
Placebo
Twice daily for 3 days
Dexamethasone
0.15 mg/kg/dose twice daily for 3 days

Locations

Country Name City State
United States Nationwide Children's Hospital in Columbus Columbus Ohio
United States American Family Children's Hospital Madison Wisconsin
United States Children's Hospital of Pittsburgh Pittsburgh Pennsylvania
United States Hasbro Children's Hospital Providence Rhode Island
United States Primary Children's Hospital Salt Lake City Utah
United States Children's National Medical Center Washington District of Columbia

Sponsors (2)

Lead Sponsor Collaborator
Nader Shaikh National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Distribution of Children With Renal Scarring at the Outcome Dimercaptosuccinic Acid (DMSA) Renal Scan Renal scarring was defined as decreased uptake of tracer with or without loss of contours. Three radiologists independently reviewed for scarring all DMSA scans that were of adequate quality. For a given kidney, the presence or absence of scarring was the diagnosis endorsed by the majority of readers, i.e. 2 of 3. For a given child, if either kidney or both kidneys were diagnosed with scarring by the majority of readers, then the child was determined to have renal scarring. The outcome DMSA scan was 5-24 months from enrollment. The mean number of months was 6.1.
Primary The Distribution of Children With Severe Renal Scarring at the Outcome Dimercaptosuccinic Acid (DMSA) Renal Scan Renal scarring was defined as decreased uptake of tracer with or without loss of contours. Scarring was assessed semi-quantitatively by dividing the renal cortex into 12 equal segments. Severe scarring was defined as greater than 4 affected renal segments or global atrophy, i.e. diffuse scarring or shrunken kidney. Three radiologists independently reviewed for scarring all DMSA scans that were of adequate quality. For a given kidney, the presence or absence of severe scarring was the diagnosis endorsed by the majority of readers, i.e. 2 of 3. For a given child, if either kidney or both kidneys were diagnosed with severe scarring by the majority of readers, then the child was determined to have severe renal scarring. The outcome DMSA scan was 5-24 months from enrollment. The mean number of months was 6.1.
Secondary The Mean Proportion of Children With Renal Scarring at the Outcome Dimercaptosuccinic Acid (DMSA) Renal Scan Taken Across the 3 Radiologists Renal scarring was defined as decreased uptake of tracer with or without loss of contours. Three radiologists independently reviewed for scarring all DMSA scans that were of adequate quality. For each radiologist, for each child, if either kidney or both kidneys were diagnosed with scarring, then the child was determined to have renal scarring. For each radiologist, the proportion of children with scarring in a given treatment group is the number of children diagnosed with scarring divided by the number of children in the treatment group. The mean proportion of children with scarring in a given treatment group is the average proportion taken across the 3 radiologists. The outcome DMSA scan was 5-24 months from enrollment. The mean number of months was 6.1.
See also
  Status Clinical Trial Phase
Completed NCT03235947 - Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients Phase 4
Withdrawn NCT01881165 - Cranberry on Urinary Tract Infections Phase 4
Terminated NCT02198833 - Efficacy of Micro-Patterned Foley Catheter to Reduce Catheter-Associated Urinary Tract Infection N/A
Completed NCT01687114 - Urinary Proanthocyanidin-A2 as a Biomarker of Compliance to Intake of Cranberry Products N/A
Completed NCT02357758 - Effects of Antibiotic Prophylaxis on Recurrent UTI in Children Phase 4
Completed NCT01219595 - Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible Women N/A
Completed NCT00365430 - SAFE or SORRY? Patient Safety Study of the Prevention of Adverse Patient Outcomes N/A
Recruiting NCT04502095 - Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy Phase 4
Completed NCT00976963 - Single Dose Monurol for Treatment of Acute Cystitis N/A
Recruiting NCT02568800 - Prolonged Infusion Cefepime and Nosocomial Infections Phase 3
Completed NCT02785445 - Healthy.io Method Comparison & User Performance Study N/A
Completed NCT02216253 - L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract to Prevent Postoperative Urinary Tract Infection. N/A
Completed NCT01478620 - Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI) Phase 3
Completed NCT01054690 - Silver Alloyed Urinary Catheters and Incidence of Catheter Acquired Urinary Tract Infections (UTI) N/A
Completed NCT00371631 - Colonizing Neurogenic Bladders With Benign Flora Phase 1
Terminated NCT03697993 - Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS) Phase 4
Terminated NCT01803919 - Efficacy Study of Antimicrobial Catheters to Avoid Urinary Infections in Spinal Cord Injured Patients N/A
Enrolling by invitation NCT01231737 - Efficacy of Two Prophylactic Schedules (Prulifloxacin Versus Phosphomycin) Phase 2
Completed NCT01763008 - A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections Phase 4
Completed NCT00528476 - Risk Factors for Recurrent Urinary Tract Infection in Children N/A